Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more
Abivax SA (ABVX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.139x
Based on the latest financial reports, Abivax SA (ABVX) has a cash flow conversion efficiency ratio of -0.139x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-71.28 Million) by net assets (€511.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Abivax SA - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Abivax SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Abivax SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abivax SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dixon Technologies (India) Limited
NSE:DIXON
|
0.044x |
|
HUB24 Ltd
AU:HUB
|
0.156x |
|
NKT A/S
PINK:NRKBF
|
0.036x |
|
Zhejiang Dahua Technology Co Ltd
SHE:002236
|
0.024x |
|
UPL Limited
NSE:UPL
|
-0.128x |
|
Telephone and Data Systems Inc
NYSE:TDS
|
-0.007x |
|
Texas Capital Bancshares Inc
NASDAQ:TCBI
|
0.036x |
|
Shenzhen Transsion Holdings Co Ltd
SHG:688036
|
0.165x |
Annual Cash Flow Conversion Efficiency for Abivax SA (2013–2024)
The table below shows the annual cash flow conversion efficiency of Abivax SA from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €40.58 Million | €-154.07 Million | -3.796x | -666.11% |
| 2023-12-31 | €196.01 Million | €-97.13 Million | -0.496x | +98.58% |
| 2022-12-31 | €1.88 Million | €-65.58 Million | -34.845x | -2096.03% |
| 2021-12-31 | €28.77 Million | €-45.66 Million | -1.587x | +75.14% |
| 2020-12-31 | €4.67 Million | €-29.82 Million | -6.382x | -173.67% |
| 2019-12-31 | €11.78 Million | €-27.47 Million | -2.332x | -453.39% |
| 2018-12-31 | €34.65 Million | €-14.60 Million | -0.421x | -140.30% |
| 2017-12-31 | €48.18 Million | €-8.45 Million | -0.175x | +36.28% |
| 2016-12-31 | €56.72 Million | €-15.61 Million | -0.275x | -32.46% |
| 2015-12-31 | €71.74 Million | €-14.90 Million | -0.208x | -113.32% |
| 2014-12-31 | €33.94 Million | €-3.31 Million | -0.097x | -0.25% |
| 2013-12-31 | €34.02 Million | €-3.31 Million | -0.097x | -- |